Shares of Athenex Inc (NASDAQ:ATNX) have earned a consensus recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $27.80.
Several equities research analysts recently weighed in on ATNX shares. JPMorgan Chase & Co. started coverage on Athenex in a report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price objective for the company. Deutsche Bank set a $20.00 price objective on Athenex and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a report on Thursday, January 4th.
Institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new stake in Athenex in the 3rd quarter worth about $198,000. Bank of New York Mellon Corp purchased a new stake in Athenex in the 2nd quarter worth about $240,000. Tudor Investment Corp ET AL purchased a new stake in Athenex in the 2nd quarter worth about $320,000. Schwab Charles Investment Management Inc. purchased a new stake in Athenex in the 3rd quarter worth about $524,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Athenex in the 2nd quarter worth about $601,000. 3.11% of the stock is owned by institutional investors.
Athenex (NASDAQ:ATNX) last announced its earnings results on Thursday, November 9th. The company reported ($0.30) earnings per share (EPS) for the quarter. analysts predict that Athenex will post -2.3 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Athenex Inc (ATNX) Receives Consensus Rating of “Buy” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/29/athenex-inc-atnx-receives-consensus-rating-of-buy-from-brokerages.html.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.